Linda Nguyen1, Laura R Lander2, Kevin E O'Grady3, Patrick J Marshalek2, Adrienne Schmidt4,5, Audra K Kelly6, Hendrée E Jones4,5. 1. Departments of Neurosciences and Pediatrics, University of California, San Diego, San Diego, California. 2. Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, West Virginia. 3. Department of Psychology, University of Maryland, College Park, College Park, Maryland. 4. UNC Horizons and Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 5. Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 6. School of Medicine West Virginia University, Morgantown, West Virginia.
Abstract
BACKGROUND AND OBJECTIVES: Rising concerns regarding diversion and misuse of mono-buprenorphine for treatment of pregnant women with opioid use disorders have sparked interest in the use of buprenorphine + naloxone to reduce misuse and diversion rates. Examined the relationship of prenatal buprenorphine + naloxone exposure to neonatal outcomes. METHODS: This is a retrospective chart review of 26 mother infant dyads in comprehensive medication-assisted treatment with buprenorphine + naloxone during pregnancy. RESULTS: All neonatal birth outcome parameters were within normal ranges, albeit on the lower side of normal for gestational age and birth weight. Only 19% of neonates required morphine pharmacology for NAS. CONCLUSIONS: Use of buprenorphine + naloxone shows relative safety in pregnancy. SCIENTIFIC SIGNIFICANCE: These findings can help better guide prescribing practices for pregnant patients at risk for misuse or diversion of buprenorphine. (Am J Addict 2018;27:92-96).
BACKGROUND AND OBJECTIVES: Rising concerns regarding diversion and misuse of mono-buprenorphine for treatment of pregnant women with opioid use disorders have sparked interest in the use of buprenorphine + naloxone to reduce misuse and diversion rates. Examined the relationship of prenatal buprenorphine + naloxone exposure to neonatal outcomes. METHODS: This is a retrospective chart review of 26 mother infant dyads in comprehensive medication-assisted treatment with buprenorphine + naloxone during pregnancy. RESULTS: All neonatal birth outcome parameters were within normal ranges, albeit on the lower side of normal for gestational age and birth weight. Only 19% of neonates required morphine pharmacology for NAS. CONCLUSIONS: Use of buprenorphine + naloxone shows relative safety in pregnancy. SCIENTIFIC SIGNIFICANCE: These findings can help better guide prescribing practices for pregnant patients at risk for misuse or diversion of buprenorphine. (Am J Addict 2018;27:92-96).
Authors: Kimberly A Hekman; Violanda I Grigorescu; Lorraine L Cameron; Corinne E Miller; Ruben A Smith Journal: Am J Prev Med Date: 2013-07 Impact factor: 5.043
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Ingunn O Lund; Gabriele Fischer; Gabrielle K Welle-Strand; Kevin E O'Grady; Kimber Debelak; William R Morrone; Hendrée E Jones Journal: Subst Abuse Date: 2013-03-14
Authors: Erin L Winstanley; Laura R Lander; James H Berry; James J Mahoney; Wanhong Zheng; Jeremy Herschler; Patrick Marshalek; Sheena Sayres; Jay Mason; Marc W Haut Journal: J Subst Abuse Treat Date: 2019-05-08
Authors: Julia Brennan; Caleb Wiedeman; John R Dunn; William Schaffner; Timothy F Jones Journal: Public Health Rep Date: 2019-08-07 Impact factor: 2.792
Authors: Laura R Lander; Wanhong Zheng; Jeremy D Hustead; James J Mahoney; James H Berry; Patrick Marshalek; Erin L Winstanley Journal: J Neurol Sci Date: 2020-02-03 Impact factor: 3.181
Authors: Theresa Winhusen; Michelle Lofwall; Hendrée E Jones; Christine Wilder; Robert Lindblad; Davida M Schiff; Scott Wexelblatt; Stephanie Merhar; Sean M Murphy; Shelly F Greenfield; Mishka Terplan; Elisha M Wachman; Frankie Kropp; Jeff Theobald; Mitra Lewis; Abigail G Matthews; Connie Guille; Michael Silverstein; Carmen Rosa Journal: Contemp Clin Trials Date: 2020-04-27 Impact factor: 2.226